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Small polykaryocytes resulting from cell fusion are found in herpes simplex virus (HSV) lesions in patients, but their significance for viral
spread and pathogenesis is unclear. Although syncytial variants causing extensive fusion in tissue culture can be readily isolated from
laboratory strains, they are rarely found in clinical isolates, suggesting that extensive cell fusion may be deleterious in vivo. Syncytial
mutations have previously been identified for several laboratory strains, but not for clinical isolates of HSV type 2. To address this deficiency,
we studied a recent syncytial clinical isolate, finding it to be a mixture of two syncytial and one nonsyncytial strain. The two syncytial strains
have novel mutations in glycoprotein B, and in vitro cell fusion assays confirmed that they are responsible for syncytium formation. This
panel of clinical strains may be ideal for examining the effect of increased cell fusion on pathogenesis.
D 2004 Elsevier Inc. All rights reserved.
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Viruses in many families have the ability to cause fusion
of infected cells with neighboring uninfected cells to
produce multinucleated giant cells. For herpes simplex
virus (HSV), such cell–cell fusion is one of three routes by
which the virus can infect cells (Spear, 1993), the others
being entry of cell-free virions by fusion of the virus
envelope with either the cell plasma membrane (Fuller and
Spear, 1987; Morgan et al., 1968; Wittels and Spear, 1990)
or an endosomal membrane (Nicola et al., 2003), and a
poorly understood pathway in which the virus can spread
from an infected cell to a neighboring uninfected cell even0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.07.027
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E-mail address: mmugge@lsuhsc.edu (M.I. Muggeridge).in the presence of antibodies that neutralize cell-free virus
(Dingwell et al., 1994; Minson et al., 1986).
Multinucleated cells (polykaryocytes) were first
described in HSV lesions in patients many years ago, and
were used for diagnostic purposes (Blank et al., 1951).
However, their significance for replication and spread of the
virus in vivo has been unclear, partly because the degree of
cell fusion produced by different clinical isolates and
laboratory strains in tissue culture varies enormously. Early
studies described the presence of polykaryocytes when cells
in culture were infected either with HSV that had been
passaged in mouse brains after isolation from a patient
(Scherer and Syverton, 1954), or with a laboratory strain of
HSV (Sosa-Martı´nez et al., 1955). Furthermore, primary eye
isolates produced polykaryocytes on cultured cells (Doane
et al., 1955), as did primary oral isolates (Gray et al., 1958;
Scott and McLeod, 1959).
The HSV-induced polykaryocytes described above (both
in lesions and in tissue culture) generally contained no more04) 244–253
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multinucleated giant cellsQ (Gray et al., 1958). However,
viral variants that cause much more extensive fusion in
tissue culture can be readily isolated from laboratory
stocks with or without mutagenesis, and the resulting
multinucleated cells (referred to as syncytia) may contain
hundreds or thousands of nuclei (Cassai et al., 1975/1976;
Hoggan and Roizman, 1959; Read et al., 1980; Tognon et
al., 1984; Wheeler, 1960). There have also been reports of
clinical isolates that form syncytia in tissue culture,
although these are certainly the exception (Aurelian et
al., 1974; Gray et al., 1958; Munk and Donner, 1963;
Munk and Ludwig, 1972; Scott and McLeod, 1959; Terni
and Roizman, 1970).
Sequence changes that confer a syncytial phenotype are
referred to as syn mutations, and analysis of laboratory-
derived syncytial variants mapped such mutations to several
loci in the genome of HSV type 1 (HSV-1). One locus
corresponds to the cytoplasmic tail of glycoprotein B (gB)
(Ruyechan et al., 1979), one of the four viral proteins
required for membrane fusion during virus entry, and it was
found that certain single amino acid changes in this region
are responsible (Bzik et al., 1984; Engel et al., 1993; Gage
et al., 1993; Haanes et al., 1994; Walev et al., 1994).
Similarly, mutation of a single residue in HSV type 2 (HSV-
2) gB, which is 87% identical to gB of HSV-1, is
responsible for the syncytial phenotype of a laboratory
variant (Muggeridge, 2000). The observation that only one
amino acid substitution is required, combined with the fact
that clinical isolates of HSV-1 and HSV-2 are rarely
syncytial, suggests that a syncytial phenotype is deleterious
to these viruses in vivo. Some support for this possibility
comes from studies of virus virulence in animal models, the
majority of which have found that syncytial viruses are
attenuated (Cassai et al., 1975/1976; Schneweis et al., 1984;
Wheeler, 1960, 1964).
The syn locus in clinical isolates has been identified in
only two cases (HSV-1 ANG and HSV-1 Fr), both of which
have an amino acid substitution in the gB cytoplasmic tail
(Haanes et al., 1994; Walev et al., 1994; Weise et al., 1987).
A better understanding of the relevance of cell–cell fusion to
spread of the virus in vivo, and of the effect of syn
mutations on pathogenesis, would be aided by the avail-
ability of well-characterized syncytial clinical isolates and
related nonsyncytial viruses. To this end, we have begun to
characterize the HSV-2 clinical isolate Burr, which came
from a genital lesion and was syncytial when plated on Vero
cells (Johnson, 2002). Unfortunately, there is no information
on the pathogenesis of the virus in the patient from whom it
was isolated. We found that the isolate was in fact a mixture
of at least three related viruses, of which one was
nonsyncytial, and two were syncytial. We determined that
both of the latter have novel syn mutations in gB, and these
are the first syn mutations to be identified in clinical isolates
of HSV-2. This panel of three viruses may therefore prove to
be ideal for examining the effect of increased cell–cellfusion on pathogenesis in an animal model of HSV-2
infection.Results
Effect of cyclosporin A (CyA) on plaque formation by HSV-2
clinical isolate Burr
Preliminary information on the location of syn muta-
tions in HSV-1 and HSV-2 can be obtained by examining
the effect of the cyclic oligopeptide CyA on syncytium
formation. CyA has no effect if the syn mutation is in gB,
whereas it inhibits cell–cell fusion (by an unknown
mechanism) if the syn mutation is in any other locus,
such as the gK or UL24 proteins (Muggeridge, 2000;
Walev et al., 1991, 1994). Therefore, the effect of CyA on
HSV-2 Burr plaque formation was compared with its effect
on HSV-2 333syn2 and 333syn6, two previously charac-
terized syncytial variants derived from the nonsyncytial
HSV-2 laboratory strain 333 (Muggeridge, 2000). As
shown in Fig. 1, it blocked fusion by 333syn2, which
has a syn mutation in UL24 (panels A and B), but had no
effect on fusion by 333syn6, which has a syn mutation in
gB (panels C and D), or on HSV-2 Burr (panels E and F).
This suggested that the syn mutation in HSV-2 Burr lies
within gB.
Because all known syn mutations in gB are within the
cytoplasmic tail, a 0.7-kb DNA fragment containing the
relevant coding region was amplified by PCR, using
infected cell DNA as template, and subjected to direct
sequencing. This produced overlapping ladders of bands
with some primers, suggesting that the viral stock was
actually a mixture (data not shown). Supporting evidence
for this possibility was obtained when the PCR product was
cloned into plasmid pCR2.1 (Invitrogen). Digestion of the
resulting clones to determine which ones contained inserts
showed that there were two distinguishable insert sizes (data
not shown).
Plaque purification of components of HSV-2 clinical isolate
Burr
When CV1 cells were infected with HSV-2 Burr at a low
multiplicity, such that individual plaques could be observed,
three different plaque phenotypes were seen (Fig. 2). One
was syncytial with spaces within the plaques (panel B), one
was syncytial with no gaps within the plaques (panel C), and
one was nonsyncytial (panel A). Viruses producing each of
these plaque phenotypes were plaque-purified three times;
henceforth, the syncytial variants will be referred to as Burr
syn1 (panel B) and Burr syn3 (panel C), respectively, and
the nonsyncytial virus will be referred to as strain Burr.
Syncytium formation by Burr syn1 and Burr syn3 was
resistant to CyA (panels D–G), suggesting that both viruses
have syn mutations within gB. Note that the CyA experi-
Fig. 1. Effect of CyA on cell–cell fusion. COS7 cells were infected with HSV-2 333syn2 (A and B), HSV-2 333syn6 (C and D), or HSV-2 Burr (E and F). CyA
was added to dishes B, D, and F. The cells were stained at 24 h post-infection.
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cells, there was a difference in plaque morphology between
Burr syn1 and Burr syn3. The former (panels D and E) had
spaces within the plaques, whereas the latter (panels F and
G) did not. For the Burr syn3 plaques, the clear areas
between the large central cluster of nuclei and the smaller
satellite clusters are cytoplasm and not bare tissue culture
plastic.
Identification of mutations in Burr syn1 and Burr syn3 gB
The entire gB gene of the nonsyncytial Burr strain was
sequenced, using uncloned PCR fragments as templates.
The sequence data (not shown) are available from GenBank
under accession no. AY630441. There were two nucleotide
differences when compared to the published sequence of
strain 333 gB (Stuve et al., 1987; Zwaagstra and Leung,
1987). One of these resulted in the alteration of residue 374from Gln (CAG) to Glu (GAG); the other was a silent
change at codon 386 (ATT to ATC). Note that we use the
numbering system of Pereira et al. (1989), such that the first
amino acid of the mature protein, after removal of the signal
peptide, is designated residue one. The gB genes of Burr
syn1 and Burr syn3 were then sequenced and compared to
the Burr sequence. The sequence data are available from
GenBank under accession nos. AY627356 and AY630440.
Each was found to have a mutation in the region encoding
the cytoplasmic tail, neither of which had previously been
found in any syncytial variant (Fig. 3). Burr syn3 had a
single nucleotide change, resulting in a Thr to Pro
substitution at residue 837. This amino acid change is close
to several others previously found in syncytial variants, a
region referred to by Gage et al. (1993) as syn region II.
Burr syn1 had a 35-nucleotide duplication, resulting in a
frameshift; consequently, the final 34 residues of the gB
cytoplasmic tail (underlined) would be replaced by 56 new
Fig. 2. Plaque phenotypes produced by purified components of original Burr clinical isolate, and effect of CyA. CV1 cells (A–C) or COS7 cells (D–G) were
infected with HSV-2 Burr (A), HSV-2 Burr syn1 (B, D, E), or HSV-2 Burr syn3 (C, F, G). CyA was added to dishes E and G. The cells were stained at 24 h
post-infection.
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mutation in a syncytial variant.
Syncytial activity of gB mutants
To determine if these mutations do indeed confer a
syncytial phenotype, they were first introduced into a
plasmid that expresses wild-type (i.e., nonsyncytial) gB
from strain 333 (see Materials and methods). For conven-
ience, the modified proteins will be referred to here as Burr
syn1 gB, Burr syn3 gB, and Burr gB, although they differ
from the viral-encoded proteins at residue 374 in the
ectodomain. Two assays for cell–cell fusion were per-
formed, using plasmids expressing gB from strain 333 and
from variant 333syn6 (which has an E835D syn mutation)
as controls.In the first assay (Figs. 4A–E), COS7 cells were
transfected with a gB plasmid, such that about 20% of the
cells expressed the protein, and then incubated with the gB-
minus virus K082 at a multiplicity of 0.05 so that only a
minority of the cells were infected. Under these conditions,
virus replication in cells expressing wild-type gB allows the
production of phenotypically complemented virions, which
then infect neighboring cells. A second cycle of replication
occurs, causing the cells to round up, but the progeny
virions lack gB and consequently are noninfectious. Thus,
small plaques consisting of rounded-up cells can be seen by
48 h post-infection (p.i.), but no CPE is visible at 24 h p.i.
and there is no detectable cell fusion at any time point. In
contrast, virus replication in cells expressing gB with a syn
mutation results in fusion of infected cells with surrounding
uninfected cells, such that large syncytial plaques are visible
Fig. 3. Amino acid sequences of the cytoplasmic tails of gB from HSV-2 Burr, Burr syn1, and Burr syn3. The arrowheads indicate residues previously found to
be altered in syn mutants of HSV-1 or HSV-2, and the boxed region indicates where truncations of HSV-2 strain 333 gB produce a syncytial phenotype. The C-
terminal 34 residues (underlined) of Burr and Burr syn3 gB are replaced by 56 unrelated residues in Burr syn1 gB as a result of a frameshift. Note that the
numbering system uses the first residue of the mature protein as residue 1.
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after infection of cells expressing strain 333 gB (panel A),
whereas syncytial plaques were observed after infection of
cells expressing strain 333syn6 gB (panel B). Crucially,
syncytial plaques were also seen after infection of cells
expressing Burr syn1 gB or Burr syn3 gB (panels D and E),
but not Burr gB (panel C). In this assay, the syncytial plaque
morphology was the same regardless of which syn mutation
in gB was present (panels B, D, and E); there were no
syncytial plaques with spaces. Two possible explanations
are that: (i) HSV-1 strain KOS (the parent strain of the K082
gB-null mutant) may not be a suitable background for this
plaque morphology; (ii) expression of gB in transfected
cells followed by infection with gB-null virus may preclude
this morphology.
The second assay relies on our previous finding that
coexpression of wild-type strain 333 gB with gD, gH, and
gL in transfected COS7 cells is sufficient to cause cell–cell
fusion, and that the degree of fusion is increased if wild-type
gB is replaced with gB carrying a syn mutation (Mugger-
idge, 2000). Therefore, each of the three forms of Burr gB
was coexpressed with gD, gH, and gL, and the degree of
fusion was compared with that obtained when either wild-
type 333 gB or 333syn6 gB was used. The results were
similar to those obtained in the first assay, in that Burr syn1
and Burr syn3 gB (panels I and J), like 333syn6 gB (panel
G), had greater activity than 333 gB (panel F), whereas Burr
gB (panel H) did not. The concordant results of the two
assays confirm that the syncytial phenotypes of viruses Burr
syn1 and Burr syn3 are due to their mutations in the gB
cytoplasmic tail.
Cell surface expression of Burr gB proteins
A YXXL motif at residues 867–870 in the HSV-2 gB
cytoplasmic tail has previously been shown to influence the
amount of the protein found at the cell surface; a mutant inwhich tyrosine 867 was changed to alanine (Y867A), and
also a panel of truncation mutants lacking this sequence, all
had higher surface expression levels than the wild-type
protein. The truncation mutants had increased activity in
cell–cell fusion assays, but the Y867A mutant did not,
demonstrating that a syncytial phenotype is not due to
increased cell surface expression of gB (Fan et al., 2002). It
was therefore of interest to examine the cell surface
expression levels of the three forms of Burr gB, especially
as Burr syn1 gB lacks the final 34 residues of the
cytoplasmic tail, including the YXXL motif. This was
tested by immunofluorescence, first in transfected cells
expressing the relevant proteins, and then in infected cells
(Fig. 5).
As found previously, wild-type strain 333 gB had a
relatively low level of cell surface expression in transfected
cells (panel A) (Fan et al., 2002). A similar result was found
with Burr gB and Burr syn3 gB (panels B and D), whereas
Burr syn1 gB was present in greater abundance at the cell
surface (panel C). Thus, the behavior of the various forms of
Burr gB is consistent with what we previously observed
with truncation mutants: If the YXXL motif is missing, cell
surface expression is increased. Therefore, it was somewhat
surprising that in infected cells, surface expression of gB
was similar for each of the four viruses (panels E–H). This
suggests that the control of membrane protein trafficking by
recognition of sequence motifs may be altered by infection,
but nonetheless is entirely consistent with our previous
finding that syncytial activity is not due to an increased cell
surface level of gB.Discussion
Syncytial variants of HSV-1 and HSV-2 can be readily
isolated from nonsyncytial laboratory strains by successive
rounds of plaque purification, and they maintain this
Fig. 4. Effect of mutations in gB on cell fusion. COS7 cells were either
transfected with a plasmid expressing a form of gB, and then infected with
the gB-minus virus K082 (A–E), or cotransfected with plasmids expressing
gD, gH, gL, and a form of gB, and then overlaid with untransfected cells
(F–J). The infected cells were stained at 24 h post-infection; the transfected
cells were stained at 48 h after overlay. (A and F) 333 gB; (B and G) 333
syn6 gB; (C and H) Burr gB; (D and I) Burr syn1 gB; (E and J) Burr syn3
gB. Note that the magnification is five times greater in panels F–J than in
A–E.
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syncytial clinical isolates of either virus are extremely rare
(Johnson, F.B., unpublished data), suggesting that syncy-
tium formation may be deleterious to the virus in vivo. Synmutations have been mapped to several viral genes, and
Haffey and Spear (1980) stated that bthe fusion-inducing or
syncytial (syn) phenotype can be considered a mutant
phenotype resulting from the absence or failure of the viral
gene products that modulate or inhibit fusion-inducing
activityQ. Unfortunately, however, there is still no informa-
tion on the mechanism(s) by which syn mutations exert their
effect.
All of the syn mutations identified in gB are within its
cytoplasmic tail. For HSV-1 gB, they are R766C, R770W,
T783I, L787H, L787P, S824F, A825V, R828H, and R828C
(Bzik et al., 1984; Engel et al., 1993; Gage et al., 1993;
Haanes et al., 1994; Walev et al., 1994). Targeted insertion
of four amino acids between E786 and L787 also produces a
syncytial phenotype (Cai et al., 1988a). For HSV-2 gB, the
known syn mutations are E835D (Muggeridge, 2000),
R836H (Muggeridge, M.I., unpublished), and LL849/
850AA (Fan et al., 2002), which correspond to E827,
R828, and LL840/841 in HSV-1 gB.
The only information on syn loci in clinical isolates is for
HSV-1 ANG, a genital isolate (Munk and Ludwig, 1972),
and HSV-1 Fr, an eye isolate (Walev et al., 1994). Both have
mutations in gB: an A825V change for ANG (Haanes et al.,
1994; Weise et al., 1987) and an S824F change for Fr
(Walev et al., 1994). Therefore, the description of a genital
clinical isolate of HSV-2 with a syncytial phenotype was
intriguing (Johnson, 2002). Our preliminary experiments
with this virus suggested that the initial clinical isolate was
in fact a mixture, and this was confirmed by plating at low
multiplicity to observe individual plaques. Three distinct
strains were isolated from the stock, of which one (now
referred to as Burr) is nonsyncytial, and two (Burr syn1 and
Burr syn3) are syncytial.
Determination of the complete gB coding sequence of
plaque-purified HSV-2 Burr showed that only residue 374
differed from the published sequence of strain 333 gB.
This residue appears to be polymorphic. It is Gln in strains
333 and HG52 (Bzik et al., 1986; Stuve et al., 1987;
Zwaagstra and Leung, 1987) and in two of five non-
syncytial HSV-2 clinical isolates studied by Terhune et al.
(1998), but Glu in Burr, strain G (Lee, H.H., GenBank
accession number AF295528), and in the other three
clinical isolates (Terhune et al., 1998). Sequencing of Burr
syn1 and Burr syn3 gB showed that they are different to
Burr and to each other in the cytoplasmic tail region. Burr
syn3 has a single nucleotide change, resulting in substitution
of Pro for Thr at residue 837, whereas Burr syn1 has a 35
nucleotide duplication, resulting in a frameshift. The
frameshift causes the final 34 residues of the protein to be
replaced with a different sequence of 56 residues, demon-
strating that three motifs in the cytoplasmic tail (a YXXL, a
dileucine, and a C-terminal acidic cluster) are dispensable
for virus replication.
The ability of these mutations to confer a syncytial
phenotype was confirmed by introducing them into a cloned
copy of the strain 333 gB gene. Both mutations increased
Fig. 5. Effect of mutations in gB on cell surface expression. COS7 cells were either transfected with a plasmid expressing a form of gB (A–D), or infected with
various strains of HSV-2 (E–H). They were stained by immunofluorescence (without permeabilization) 48 h after transfection (A–D) or 10.5 h after infection
(E–H). (A) 333 gB; (B) Burr gB; (C) Burr syn1 gB; (D) Burr syn3 gB; (E) strain 333; (F) Burr; (G) Burr syn1; (H) Burr syn3.
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coexpressed in transfected cells, and both resulted in the
formation of syncytial plaques when cells expressing gB
were superinfected with a gB-null virus. As yet, we have no
information on the mechanism by which the mutations
affect membrane fusion, but the frameshift in Burr syn1 gB
presumably acts in a similar way to various targeted C-
terminal truncations of gB, which also result in a syncytial
phenotype (Fan et al., 2002; Foster et al., 2001). Truncations
that remove a putative YXXL endocytosis motif result in a
higher level of gB on the surface of transfected cells, with or
without superinfection with a gB-null virus, as does
mutation of the motif itself; however, whereas truncations
increase fusion, mutation of the YXXL motif does not (Fan
et al., 2002). Therefore, the syncytial phenotype in these
assays is not caused by increasing the surface level of gB.In this study, Burr syn1 gB was found to have a relatively
high level of surface expression in transfected cells, as
would be predicted from the absence of the YXXL motif.
However, in cells infected with the Burr syn1 virus, the
surface level of gB was no higher than in cells infected with
the other viruses. Despite this unexplained difference
between transfected and infected cells, the fact that gB
surface expression was not increased for either Burr syn1 or
Burr syn3 confirms that such an increase is not the
mechanism responsible for a syncytial phenotype.
The possibility that one or both of the syncytial variants
arose during initial tissue culture, rather than in the patient
from whom the isolate was derived, is considered unlikely.
This is because the three plaque phenotypes (two syncytial
and one nonsyncytial) were present in approximately equal
numbers when first passage virus was plated on CV1 cells,
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stocks of nonsyncytial strains requires several rounds of
enrichment by plaque purification. Furthermore, the possi-
bility that the viruses are unrelated, despite being isolated
from the same lesion, is rendered unlikely by comparison of
sequences for the gK gene. The gK genes of Burr, Burr
syn1, and Burr syn3 are identical (sequence data, not shown,
are available from GenBank under accession no.
AY632897), whereas comparison with the gK sequences
of HSV-2 strain HG52 (Dolan et al., 1998), and of strain 333
(available from GenBank under accession no. AY631854),
revealed differences with one or both at nine codons (Table
1). Thus, at two positions the Burr strains and 333 differ
from HG52, at five positions the Burr strains and HG52
differ from 333, and at two positions the Burr strains differ
from 333 and HG52.
These newly characterized viruses will likely prove
useful for determining how syn mutations in gB work.
Moreover, as HSV-2 clinical isolates with a coisolated
nonsyncytial virus for comparison, they will be invaluable
for studying the relevance of cell fusion to virulence using
the mouse intravaginal model of infection. A previous study
found that a panel of several syncytial HSV-1 and HSV-2
strains was less virulent than a panel of nonsyncytial HSV-1
strains in this model (Schneweis et al., 1984), but as there
was no clear relationship between the two panels of viruses,
and the syn mutations were for the most part unmapped,
further work is necessary to determine if enhanced cell
fusion is indeed deleterious to the virus.Materials and methods
Cells, viruses, and antibodies
COS7 and CV1 cells were obtained from ATCC, and
were grown in DMEM supplemented with 5% fetal bovine
serum (FBS). D6 cells, an HSV-1 gB-expressing cell line,
were obtained from Stanley Person and were grown in
DMEM containing 5% FBS and 0.2 mg/ml G418 (Cai et al.,
1987). The HSV-2 strain Burr used as starting material for
these studies was one passage from primary isolation, andTable 1
Sequence differences in the gK gene of HSV-2 strains
Burr Burr syn1
Codon 46 GCA (Ala) GCA (Ala)
Codon 80 CGC (Arg) CGC (Arg)
Codon 214 GTT (Val) GTT (Val)
Codon 247 CAC (His) CAC (His)
Codon 274 GGC (Gly) GGC (Gly)
Codon 288 CAC (His) CAC (His)
Codon 306 GGG (Gly) GGG (Gly)
Codon 322 CTC (Leu) CTC (Leu)
Codon 323 GTG (Val) GTG (Val)
a Bold text indicates a difference from the sequence of the HSV-2 Burr strain.was syncytial as a primary isolate and after passage
(Johnson, 2002). All HSV-2 viruses were propagated and
titered on CV1 cells. The gB-minus HSV-1 mutant K082
was obtained from Stanley Person, and was propagated in
D6 cells, as described previously (Cai et al., 1987). The anti-
HSV-2 gB polyclonal antibody R91 was provided by Gary
Cohen and Roselyn Eisenberg.
PCR amplification and DNA sequencing
Template DNA for PCR amplification was purified from
CV1 cells infected for 20–26 h at a multiplicity of 0.02,
using Puregene (Gentra Systems). PCR was done with Pfu
DNA polymerase, and four PCR fragments were used for
sequencing of the gB gene. These correspond to nucleotides
53305–54070, 53305–55122, 54113–55122, and 55077–
56177 in the complete DNA sequence for HSV-2 strain
HG52 (accession number Z86099) (Dolan et al., 1998). The
coding sequence for gB encompasses nucleotides 53403–
56117. Sequencing was performed with the 33P-ddNTP
ThermoSequenase kit (United States Biochemical).
Plasmids and mutagenesis
Plasmids pMM245, pMM346, pMM349, and pMM350,
which express HSV-2 strain 333 gB, glycoprotein D (gD),
glycoprotein H (gH), and glycoprotein L (gL), respectively,
were described previously (Muggeridge, 2000). Transfer of
gB mutations from HSV-2 clinical isolates into pMM245
was done as follows. Fragments corresponding to nucleo-
tides 53355–54510 (the final 1.1 kb of coding sequence
plus a short stretch of downstream noncoding sequence)
were amplified from infected cell DNA, and cloned into the
TA cloning vector pCR2.1 (Invitrogen). A 0.9-kb piece was
excised, using an XhoI site within the coding sequence and a
BamHI site at the 5V end of the downstream primer, and
used to replace the corresponding fragment in pMM245.
The resulting plasmids (pMG508, pMG509, and pMG510)
were derived from isolates Burr syn1, Burr syn3 and Burr,
respectively; DNA sequencing of the XhoI–BamHI segment
of each plasmid confirmed the absence of any extraneous
amino acid changes.Burr syn3 HG52 333
GCA (Ala) GCG (Ala)a GCA (Ala)
CGC (Arg) CGC (Arg) CAC (His)
GTT (Val) ATT (Ile) GTT (Val)
CAC (His) CAC (His) TAC (Tyr)
GGC (Gly) GGC (Gly) GAC (Asp)
CAC (His) CGC (Arg) CGC (Arg)
GGG (Gly) GGT (Gly) GGT (Gly)
CTC (Leu) CTC (Leu) CTT (Leu)
GTG (Val) GTG (Val) ATG (Met)
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Conditions for cell surface staining of cells in Nunc
Labtek chamber slides were as described previously
(Muggeridge, 2000). The primary antibody was R91, a
polyclonal anti-HSV-2 gB antibody, and the secondary
antibody was goat anti-mouse IgG-FITC (Southern Bio-
technologies).
Syncytium assay
Syncytial activity was assayed by transfecting COS7
cells in 60-mm dishes with a gB plasmid on day 1, infecting
with 1  104 PFU of K082, a gB-minus virus (Cai et al.,
1988b; Norton et al., 1998), on day 2, and observing with a
Nikon Diaphot microscope on day 3. For photography, cells
were fixed with 3% paraformaldehyde/2% sucrose in PBS
and stained with Giemsa.
Transfection-fusion assay
This assay was performed as described previously
(Muggeridge, 2000). On day 1, sparsely seeded COS7 cells
were cotransfected with plasmids expressing HSV-2 gD,
gH, gL, and either wild-type or mutant gB. On day 2, the
cells were overlaid with an excess of freshly trypsinized
untransfected cells, followed by Giemsa staining and
photography on day 3.Acknowledgments
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